Report an error   
Advanced Search

The efficacy of Roflumilast vs. Placebo in the treatment of moderate to severe COPD in the Asian population: a meta-analysis.


Kristel Kara O. Chua

Related Institution

Department of Internal Medicine - Cardinal Santos Medical Center

Publication Information

Publication Type
Book of Abstracts
Publication Sub Type
CSMC Research Abstract Compendium


BACKGROUND &  OBJECTIVES:  Roflumilast, an oral phosphodiesterase-4 (PDE-4) inhibitor, was recently included in the GOLD guidelines for use in COPD to attenuate the chronic inflammation that is central to the pathophysiology of the disease. This meta-analysis aims to determine whether Roflumilast 500 mcg once daily for 12 weeks will improve lung function in Asian patients with COPD.  

METHODS: Data was pooled from 2 randomized control trials in the Asian population with moderate to severe COPD. Outcomes measured were pre- and post-bronchodilator FEV1 at baseline and after the treatment period.  

RESULTS: The results of this meta-analysis shows that Roflumilast has a statistically significant effect in improving pre- and post-bronchodilator FEV1 compared to placebo, with a treatment effect of 81.98% and 72.83%, respectively, P < 0.00001 with a 95% confidence interval for both parameters.  

CONCLUSION:  Roflumilast 500 mcg given once a day for 12 weeks significantly improves pre- and post-bronchodilator FEV1 in Asians with moderate to severe COPD. 

Physical Location

LocationLocation CodeAvailable FormatAvailability
Cardinal Santos Medical Center - Research Center Abstract Print Format

©2022 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date